7 completed. 7 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow DNA methylation analysis: new trials by email Literature Review of DNA methylation analysis trials Research Report on DNA methylation analysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome flow cytometry, DNA methylation analysis, cytogenetic analysis - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | Case Comprehensive Cancer Center | 25 | 2010-07-01 | 2019-03-04 |
| Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma azacitidine, lenalidomide, dexamethasone - Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Case Comprehensive Cancer Center | 45 | 2010-06-01 | 2020-11-16 |
| Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma bevacizumab, temozolomide, laboratory biomarker analysis - Giant Cell Glioblastoma, Glioblastoma | Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 50 | 2010-04-28 | 2024-09-19 |
| Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus cidofovir, DNA methylation analysis, gene expression analysis - Anal Cancer, Precancerous Condition | Phase 2 | Completed | AIDS Malignancy Consortium | 33 | 2007-09-01 | 2015-12-21 |
| Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia decitabine, laboratory biomarker analysis, pharmacological study - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2007-05-01 | 2016-06-27 |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes alemtuzumab, arsenic trioxide, azacitidine - Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | Completed | The University of New South Wales | 2000 | 2006-08-01 | 2013-08-26 |
| Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes decitabine, tretinoin, DNA methylation analysis - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 54 | 2006-07-01 | 2024-05-20 |
Myelodysplastic Syndromes (3) · Anemia, Refractory, with Excess of Blasts (2) · Congenital Abnormalities (2) · Anemia, Refractory (1) · Anus Neoplasms (1) · Glioblastoma (1) · Gliosarcoma (1) · Leukemia (1) · Leukemia, Basophilic, Acute (1) · Leukemia, Eosinophilic, Acute (1) · Leukemia, Erythroblastic, Acute (1) · Leukemia, Megakaryoblastic, Acute (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Acute (1)
Case Comprehensive Cancer Center (2) · AIDS Malignancy Consortium (1) · Jonsson Comprehensive Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · The University of New South Wales (1)
United States (6) · United Kingdom (1)
Alan K. Burnett, MD, FRCP (1) · Brenda Cooper, MD (1) · Ehsan Malek, MD (1) · Elizabeth Stier, MD (1) · Frederic Reu (1) · Joel Palefsky, MD (1) · Phioanh Nghiemphu (1) · Raajit Rampal, MD, PhD (1) · William Blum (1) · Yogen Saunthararajah (1)
PMID 20368434, PMID 23032420, PMID 25621498
N01CM62207 (1), U01CA121947 (1)